Apart from etoricoxib, the formulation have other excipient.

-calcium hydrogen phosphate is widely used as a diluent. They are

small crystals and show very good compaction property.

-Calcium phosphate have a brittle deformation property. After the

compression, the tablet with calcium phosphate is hard but easily
to brittle.

-calcium phosphate is a weak alkaline. It helps to adjust the

solubility of the formulation in acid and base medium.

-calcium hydrogen phosphate anhydrous is low moisture content. It

is a good partner for moisture sensitive like etoricoxib.

From brittle deformation, the formulation should add another diluent to improve the hardness.

- MCC. It is often used as a diluent. This substance is in the

cellulose group with good compression.

-MCC can be used as a disintegrant in the formulation because

cellulose is hydrophilic, it can easily draw water into tablets without
affecting viscosity.

-MCC is highly adhesive to its particles or combined with other

drugs because the particles are bound with hydrogen bonds after
the compression. This transformation is called plastic deformation.
-The plastic deformation differs from brittle deformation in calcium
phosphate. It improves the hardness of the formulation because of
hydrogen bonds between cellulose molecules.

So, adding both diluents enhance the two properties, hardness

and compaction of the formulation.

-croscarmellose sodium is a disintegrant. it can inflate in water 4-8

times of the initial volume causing the tablets to disintegrate and
increase the surface area for better solubility.

-croscarmellose sodium is added 2-5% as a disintegrant. Should Not

adding too much because this substance makes it harder for water
to permeate the tablet.

-The last component is magnesium stearate. It is most often used as

a lubricant to improve flowability by reducing the friction between
the tablet and the socket wall.

-lubricant is added in less than 1% of the amount because adding

too much lubricants can lead to decreased tablet hardness.
To formulate the etoricoxib tablet, the formulation must have active ingredients etoricoxib,
calcium hydrogen phosphate anhydrous, microcrystalline cellulose, croscarmellose sodium, and
magnesium stearate resembling the original arcoxia. The excipients should be adjusted the
proportion to make the pharmaceutical equivalent and bioequivalent study similar to arcoxia.
The pharmaceutical equivalent is a test of dissolution and disintegration resulting f1 and f2
parameter. If the formulation passes the test then continue to the bioequivalent study resulting
AUC, Tmax, Cmax compare to the original.